As Mission Pharmacal’s president of commercial operations, Terrell Herring oversees strategy and brand positioning for the company. In addition, he focuses on product development and key new hires. Under Terrell Herring’s leadership, Mission Pharmacal also has succeeded in forging profitable new partnerships. At the beginning of 2018, Mission Pharmacal announced that it had established a partnership with Fabre-Kramer Pharmaceuticals, Inc., on a project to manufacture the antidepressant medication Travivo in extended-release tablet form. Travivo (generic name Gepirone HCL) is designed to treat generalized anxiety disorder. The two companies have elected to facilitate the transfer of the Fabre-Kramer technology to Mission for the making of registration batches of Travivo. Travivo’s advantages include its ability to function in the body without causing the types of chemical dependency, amnesia, and sexual dysfunctions that are often among the common side-effects of competing products. After Mission produces the registration batches, executives will submit the associated data to the US Food and Drug Administration as part of the agency’s review and approval process. Following anticipated FDA approval, Mission and Fabre-Kramer will focus on their joint agreement for Mission’s ongoing production of Travivo.
0 Comments
Terrell Herring serves as president of Alamo Pharma Services, a subsidiary company of Mission Pharmacal. At the latter firm, he additionally assists in directing strategic decision-making as commercial operations president. Terrell Herring and Alamo Pharma recently announced the company’s participation in a major Washington, DC conference designed to better acquaint attendees with how government regulatory processes affect innovations in the pharmaceutical industry. Alamo Pharma served as a sponsor of the FDA/CMS Summit, held toward the close of 2017. In addition, the company’s chief operating officer Peter Marchesini spoke as a member of a panel discussing the future of product-related communications, with specific reference to off-label developments. Mr. Marchesini’s panel group was moderated by journalist M. Nielsen Hobbs, whose decades of experience have informed his coverage of the pharmaceutical industry. The panel discussed the ongoing needs for training of company representatives in product knowledge and compliance requirements, and for overall fairness in labeling. KNect365, part of the Informa family of companies, hosted the summit, which also provided corporate leaders the opportunity to connect directly with regulators on issues involving formulary protocols. |
AuthorTerrell Herring began working at Mission Pharmacal Company in 2010, bringing more than 25 years of experience in the pharmaceutical industry to his role as President of Commercial Operations. Archives
February 2018
Categories
All
|